HER-2 Positive Breast Cancer Latest Advances

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Journal: BMJ (Clinical research ed.)

Published: March 16, 2026

Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.

Journal: Biochemistry and biophysics reports

Published: December 24, 2025

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Journal: Pharmaceutical research

Published: November 29, 2025

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: November 28, 2025

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Journal: Journal of medicinal chemistry

Published: November 24, 2025

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

Journal: Cells

Published: November 14, 2025

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

Journal: Nature reviews. Clinical oncology

Published: November 10, 2025

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 01, 2025

The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

Journal: International journal of molecular sciences

Published: October 21, 2025

Reducing treatment burden in HER2+ breast cancer: Evaluating subcutaneous injection methods for pertuzumab/trastuzumab combination therapy.

Journal: Medicine

Published: October 15, 2025

Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.

Journal: Analytical and bioanalytical chemistry

Published: September 19, 2025

Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer.

Journal: Scientific reports

Published: September 17, 2025

HER-2 Positive Breast Cancer Latest Advances

Find the Latest Research About HER-2 Positive Breast Cancer

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.

Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein.

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.

The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

Reducing treatment burden in HER2+ breast cancer: Evaluating subcutaneous injection methods for pertuzumab/trastuzumab combination therapy.

Reducing treatment burden in HER2+ breast cancer: Evaluating subcutaneous injection methods for pertuzumab/trastuzumab combination therapy.

Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.

Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.

Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer.

Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer.